Cargando…
Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments
SIMPLE SUMMARY: Chemo- and radiotherapy have an outstanding function in cancer treatment. In the last few years, in order to reduce the occurrence of adverse effects and to increase the efficacy of these treatments, there has been a growing interest in bringing together chemotherapeutic agents and i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268559/ https://www.ncbi.nlm.nih.gov/pubmed/34209857 http://dx.doi.org/10.3390/cancers13133263 |
_version_ | 1783720383920209920 |
---|---|
author | González, Alicia Alonso-González, Carolina González-González, Alicia Menéndez-Menéndez, Javier Cos, Samuel Martínez-Campa, Carlos |
author_facet | González, Alicia Alonso-González, Carolina González-González, Alicia Menéndez-Menéndez, Javier Cos, Samuel Martínez-Campa, Carlos |
author_sort | González, Alicia |
collection | PubMed |
description | SIMPLE SUMMARY: Chemo- and radiotherapy have an outstanding function in cancer treatment. In the last few years, in order to reduce the occurrence of adverse effects and to increase the efficacy of these treatments, there has been a growing interest in bringing together chemotherapeutic agents and ionizing radiation with other adjuvant therapies, antiangiogenic therapy being an example. Within the antitumor actions of melatonin is the inhibition of angiogenesis in diverse cancer types. In this review, we summarize present knowledge on the act of melatonin as a promising cancer cells sensitizer molecule to chemo- and radiotherapy through antiangiogenic actions. ABSTRACT: Melatonin is a hormone with different functions, antitumor actions being one of the most studied. Among its antitumor mechanisms is its ability to inhibit angiogenesis. Melatonin shows antiangiogenic effects in several types of tumors. Combination of melatonin and chemotherapeutic agents have a synergistic effect inhibiting angiogenesis. One of the undesirable effects of chemotherapy is the induction of pro-angiogenic factors, whilst the addition of melatonin is able to overcome these undesirable effects. This protective effect of the pineal hormone against angiogenesis might be one of the mechanisms underlying its anticancer effect, explaining, at least in part, why melatonin administration increases the sensitivity of tumors to the inhibitory effects exerted by ordinary chemotherapeutic agents. Melatonin has the ability to turn cancer totally resistant to chemotherapeutic agents into a more sensitive chemotherapy state. Definitely, melatonin regulates the expression and/or activity of many factors involved in angiogenesis which levels are affected (either positively or negatively) by chemotherapeutic agents. In addition, the pineal hormone has been proposed as a radiosensitizer, increasing the oncostatic effects of radiation on tumor cells. This review serves as a synopsis of the interaction between melatonin and angiogenesis, and we will outline some antiangiogenic mechanisms through which melatonin sensitizes cancer cells to treatments, such as radiotherapy or chemotherapy. |
format | Online Article Text |
id | pubmed-8268559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82685592021-07-10 Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments González, Alicia Alonso-González, Carolina González-González, Alicia Menéndez-Menéndez, Javier Cos, Samuel Martínez-Campa, Carlos Cancers (Basel) Review SIMPLE SUMMARY: Chemo- and radiotherapy have an outstanding function in cancer treatment. In the last few years, in order to reduce the occurrence of adverse effects and to increase the efficacy of these treatments, there has been a growing interest in bringing together chemotherapeutic agents and ionizing radiation with other adjuvant therapies, antiangiogenic therapy being an example. Within the antitumor actions of melatonin is the inhibition of angiogenesis in diverse cancer types. In this review, we summarize present knowledge on the act of melatonin as a promising cancer cells sensitizer molecule to chemo- and radiotherapy through antiangiogenic actions. ABSTRACT: Melatonin is a hormone with different functions, antitumor actions being one of the most studied. Among its antitumor mechanisms is its ability to inhibit angiogenesis. Melatonin shows antiangiogenic effects in several types of tumors. Combination of melatonin and chemotherapeutic agents have a synergistic effect inhibiting angiogenesis. One of the undesirable effects of chemotherapy is the induction of pro-angiogenic factors, whilst the addition of melatonin is able to overcome these undesirable effects. This protective effect of the pineal hormone against angiogenesis might be one of the mechanisms underlying its anticancer effect, explaining, at least in part, why melatonin administration increases the sensitivity of tumors to the inhibitory effects exerted by ordinary chemotherapeutic agents. Melatonin has the ability to turn cancer totally resistant to chemotherapeutic agents into a more sensitive chemotherapy state. Definitely, melatonin regulates the expression and/or activity of many factors involved in angiogenesis which levels are affected (either positively or negatively) by chemotherapeutic agents. In addition, the pineal hormone has been proposed as a radiosensitizer, increasing the oncostatic effects of radiation on tumor cells. This review serves as a synopsis of the interaction between melatonin and angiogenesis, and we will outline some antiangiogenic mechanisms through which melatonin sensitizes cancer cells to treatments, such as radiotherapy or chemotherapy. MDPI 2021-06-29 /pmc/articles/PMC8268559/ /pubmed/34209857 http://dx.doi.org/10.3390/cancers13133263 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review González, Alicia Alonso-González, Carolina González-González, Alicia Menéndez-Menéndez, Javier Cos, Samuel Martínez-Campa, Carlos Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments |
title | Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments |
title_full | Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments |
title_fullStr | Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments |
title_full_unstemmed | Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments |
title_short | Melatonin as an Adjuvant to Antiangiogenic Cancer Treatments |
title_sort | melatonin as an adjuvant to antiangiogenic cancer treatments |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268559/ https://www.ncbi.nlm.nih.gov/pubmed/34209857 http://dx.doi.org/10.3390/cancers13133263 |
work_keys_str_mv | AT gonzalezalicia melatoninasanadjuvanttoantiangiogeniccancertreatments AT alonsogonzalezcarolina melatoninasanadjuvanttoantiangiogeniccancertreatments AT gonzalezgonzalezalicia melatoninasanadjuvanttoantiangiogeniccancertreatments AT menendezmenendezjavier melatoninasanadjuvanttoantiangiogeniccancertreatments AT cossamuel melatoninasanadjuvanttoantiangiogeniccancertreatments AT martinezcampacarlos melatoninasanadjuvanttoantiangiogeniccancertreatments |